[Skip to content]

Cancer Advice - from leading UK Cancer Specialists
Find information
In this section...
On this site...

Docetaxel in locally advanced lung cancer

Although cisplatin based chemotherapy used prior to definitive therapy/surgery/RT (i.e. neoadjuvantly) may slightly improve survival in locally advanced non-small cell lung cancer, toxicity somewhat limits its advantages. At the ninth World Conference on Lung Cancer, (2000) evidence was presented that docetaxel may confer similar advantages without the same level of toxicity . Further research will be required to find the optimal chemotherapy regimen in this situation.